Mouse examine identifies novel compound which will assist develop diabetes medicine

0
386

Photo credit: CC0 Public Domain

Research from Ohio State University’s Wexner Medical Center and the College of Medicine identified a new compound that could serve as the basis for developing a new class of anti-diabetic drugs.

The study results are published online in the journal Nature Chemical Biology.

Adenosine monophosphate-activated protein kinase (Ampk) is a crucial enzyme that is involved in recording the body’s energy stores in cells. Impairment of energy metabolism occurs in obesity, which is a risk factor for diabetes. Some drugs used to treat diabetes, such as metformin, make Ampk more active.

“In our study, we discovered a protein that is involved in the removal of Ampk from cells called Fbxo48. We developed and tested a compound called BC1618 that blocks Fbxo48 and is much more effective than metformin at increasing Ampk function. BC1618 improved insulin responses, a measure of the effectiveness of diabetes drugs in obese mice, “said Dr. Rama K. Mallampalli, senior author and chairman of the Department of Internal Medicine, Ohio.

Mallampalli began this research at the University of Pittsburgh before moving to the state of Ohio and continued to work with researchers there to complete the study.

“This study builds on our previous research to understand how critical proteins are removed or broken down in the body. The research team had previously developed and manufactured a family of anti-inflammatory drugs that are FDA approved and about to enter are in phase 1 studies. ” Said Mallampalli. “With this new compound as the backbone, our team, including Dr. Bill Chen and Dr. Yuan Liu in Pittsburgh, will create other compounds that are more effective and safer in animal models and then test them in animal models of diabetes. Ultimately, we want to preserve them FDA approval for human testing. ”

Common diabetes medication reverses inflammation in the liver

More information:
Yuan Liu et al. An Fbxo48 inhibitor prevents the breakdown of pAMPKα and improves insulin resistance, Nature Chemical Biology (2021). DOI: 10.1038 / s41589-020-00723-0 Provided by Ohio State University

Quote: Mouse Study Identifies Novel Compound That May Help Diabetes Drug Development (2021, January 26), accessed January 26, 2021 from https://phys.org/news/2021-01-mouse-compound-diabetes -drugs.html

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.